Three stock market nobles make our update for this week.
Controversial hedge fund tycoon George Soros just sold three top dividend stocks. Should you follow his lead?
Momenta shares rose by more than 10% earlier today on optimism it will overcome headwinds.
Pfizer has jumped into the promising field of cancer immunotherapy with both feet. Is this effort too little, too late for the pharma giant?
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Motley Fool experts offer up insight into three intriguing small-cap biotech stocks.
Illumina gene sequencing demand could head higher thanks to President Obama's precision medicine plan.
Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.
Tired of reading through mile-long earnings reports? Have a gander at the one sentence in each of these 10 big pharma earnings reports that tells you everything you need to know about these companies.
Pfizer's management has been slowly steering the company toward a game-changing split. Will this much anticipated event finally take place in 2015?